Alnylam announces preliminary* fourth quarter and full year 2023 global net product revenues and provides additional updates

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced its preliminary* fourth quarter and full year 2023 global net product revenues for onpattro, amvuttra, givlaari, and oxlumo and provided additional updates on the products' commercial launches. preliminary fourth quarter and full year 2023 commercial and financial performance* total ttr: onpattro® (patisiran) & amvuttra® (vutrisiran) preliminary global net.
ALNY Ratings Summary
ALNY Quant Ranking